RESUMEN
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). RESULTS: The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7-not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8-28.1) in pancreatic, and 17.6 months (14.4-33.1) in bronchopulmonary NENs. [177Lu]Lu-DOTATATE exhibited scant severe toxicity. CONCLUSION: This study confirms the efficacy and safety of [177Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Tumores Neuroendocrinos , Compuestos Organometálicos , Paraganglioma , Feocromocitoma , Humanos , Octreótido/efectos adversos , Tumores Neuroendocrinos/patología , Pronóstico , Receptores de Somatostatina , Compuestos Organometálicos/efectos adversosRESUMEN
OBJECTIVE: The objective of the present study is to determine the role of sentinel lymph node (SLN) ultrastaging in apparent early-stage ovarian cancer. METHODS: We previously demonstrated the feasibility of SLN in early-stage ovarian cancer in a pilot study and in a clinical trial (NCT03452982). The SLN of the 30 patients involved in both were processed following an ultrastaging protocol. The cost of ultrastaging processing was also reported. RESULTS: A SLN was detected in up to 91.3% and 90% in the pelvic and para-aortic region, respectively. In all cases, a SLN was detected at least in one field, pelvic or para-aortic. The mean time from injection to SLN resection was 53.3 ± 20.3 min. Two of 30 (6.6%) patients had a contralateral SLN in the para-aortic field, but no patients had contralateral SLN within the pelvic field after injection. The mean number of harvested SLN was 2.1 ± 1.4 (range: 0-5) and 2.7 ± 1.5 (range: 0-7) in the pelvic and para-aortic region, respectively. Two patients were upgraded to stage IIIA1 because of lymph node metastasis. In the first case, based on single sections and haematoxylin and eosin (H&E) examination, a pelvic SLN micrometastasis (1 mm) was found on the first H&E section. By using the ultrastaging protocol, the size of the metastasis was increased to 2.1 mm (macrometastasis). In the same patient, the ultrastaging study of the inframesenteric para-cava SLNs found isolated tumour cells in the subcapsular and interfollicular lymph nodes sinus in one of the two SLN harvested (in one of the sections at the fourth and fifth ultrastage levels). The other upstaged case was a para-aortic macrometastasis in a patient in whom the SLN was not identified in the para-aortic field because of the absence of migration from the infundibulo-pelvic stump injection. The cost of ultrastaging in each patient depended on the total number of SLN retrieved, averaging 96.8 (range: 0-230.5) and 124.5 (range: 0-322.7) for pelvic and para-aortic SLN, respectively. CONCLUSIONS: A uniform protocol for ultrastaging is essential for lower-volume metastasis detection and to provide reproducible information between upcoming studies, as evidence about SLN in ovarian cancer is growing.
Asunto(s)
Adenocarcinoma/patología , Neoplasias Ováricas/patología , Biopsia del Ganglio Linfático Centinela/métodos , Ganglio Linfático Centinela/patología , Adenocarcinoma/cirugía , Adulto , Anciano , Protocolos Clínicos , Femenino , Humanos , Metástasis Linfática , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Ováricas/cirugía , Estudios Prospectivos , Ganglio Linfático Centinela/cirugíaRESUMEN
OBJECTIVE: Early-stage ovarian cancer might represent an ideal disease scenario for sentinel lymph node application. Nevertheless, the published experience seems to be limited. Our objective was to assess the feasibility and safety concerns of sentinel lymph node biopsy in patients with clinical stage I-II ovarian cancer. METHODS: We conducted a prospective cohort study of 20 patients with histologically confirmed ovarian cancer. 99mTc and indocyanine green were injected into both the utero-ovarian and infundibulopelvic ligament stump, if they were present, during surgical staging. An intraoperative gamma probe and near-infrared fluorescence imaging were used to detect the sentinel lymph nodes. Inclusion criteria included: >18 years of age, suspicious adnexal mass (unilateral or bilateral) at ultrasound and CT imaging or confirmed ovarian tumor after previous surgery (unilateral or bilateral salpingo-oophorectomy with or without hysterectomy). Adverse events were recorded through postoperative day 30. The primary trial end point was to report adverse events related to the technique, including the use of 99mTc and ICG intraperitoneally, as well as the feasibility of the technique. RESULTS: A total of 20 patients were included in the analysis. Sentinel lymph nodes were detected in 14/15 (93%) pelvic and all 20 (100%) para-aortic regions. Five patients did not have utero-ovarian injection because of prior hysterectomy. The mean time from injection to sentinel lymph node resection was 53±15 min (range; 30-80). The mean number of harvested sentinel lymph nodes was 2.2±1.5 (range; 0-5) lymph nodes in the pelvis and 3.3±1.8 (range; 1-7) lymph nodes in the para-aortic region. There were no adverse intraoperative events, nor any within the 30 days of follow-up related with the technique. CONCLUSION: Sentinel lymph node mapping in early-stage ovarian cancer is feasible without major intraoperative or < 30 days safety concerns. (NCT03452982). TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT03452982.
Asunto(s)
Neoplasias Ováricas/cirugía , Biopsia del Ganglio Linfático Centinela/métodos , Ganglio Linfático Centinela/fisiopatología , Estudios de Cohortes , Femenino , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Estudios ProspectivosRESUMEN
STUDY OBJECTIVE: To demonstrate the feasibility of laparoscopic sentinel lymph node technique in presumed early-stage ovarian cancer. DESIGN: Video illustrating the laparoscopic performance of the sentinel lymph node technique in ovarian cancer. SETTING: The Oncologic Gynecology Department at the University Hospital La Fe. PATIENTS: Candidates for the technique presented an apparent early stage ovarian cancer. The technique was performed in the context of a clinical trial called SENTOV (NCT03452982). INTERVENTIONS: To date, lymphadenectomy is recommended after the diagnosis of apparent early-stage ovarian cancer as part of the surgical staging. Minimally invasive surgery can be considered for the purpose of restaging [1]. Up to 14% of the patients are upstaged because of positive lymph nodes after pelvic and para-aortic lymphadenectomy [2]. Regarding low-grade tumors, a lower rate of lymph node involvement has been reported [3]. Sentinel lymph node technique has been reported to be feasible in a recent pilot study [4]. Two clinical trials (Sentinel Lymph Node in Early Ovarian Cancer and Sentine Lymph Node in Early Ovarian Cancer) are currently ongoing to clarify the use of sentinel lymph node technique in early ovarian cancer. The injection points were at the infundibulopelvic and ovarian ligament stumps. Two hundred microliters of saline solution containing 37 MBq of technetium-99m nanocolloid followed by 0.5 mL of indocyanine green (ICG) was injected subperitoneally. We used a 27 G needle at each injection point. Immediately after injection and also at 15 and 30 minutes after injection, the operative field was checked guided by the acoustic signal of the gamma probe and the near-infrared camera. We performed a minimum dissection looking for the sentinel lymph node or nodes in the pelvic and para-aortic region. Any lymph node with a remarkable radioactivity count as high as 10 times the background and/or dyed with ICG was considered a sentinel lymph node and was harvested separately. A systematic surgical staging was performed after the sentinel lymph node procedure was completed. Because of its small size, the ICG molecule is not caught in the lymph node valve system and keeps migrating when performing lymphography. An exhaustive direct view of the dye path is required to avoid misleading detection of the real sentinel lymph node. This theoretical problem is resolved by the use of the 99mTC-nanocolloid. This tracer gets trapped into the lymph node valve system because of its molecular size and does not keep migrating as does ICG. As such, a combination of both methods is proposed. CONCLUSION: Laparoscopic performance of sentinel lymph node technique in ovarian cancer seems to achievable. Between 2017 and 2019, this procedure was performed in 30 patients (13 laparoscopic), in the context of our pilot experience [4] and the Sentinel Lymph Node in Early Ovarian Cancer clinical trial (NCT03452982).
Asunto(s)
Carcinoma Epitelial de Ovario/patología , Laparoscopía/métodos , Escisión del Ganglio Linfático/métodos , Neoplasias Ováricas/patología , Biopsia del Ganglio Linfático Centinela/métodos , Adulto , Carcinoma Epitelial de Ovario/cirugía , Estudios de Factibilidad , Femenino , Humanos , Verde de Indocianina , Ganglios Linfáticos/patología , Ganglios Linfáticos/cirugía , Persona de Mediana Edad , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Estadificación de Neoplasias , Neoplasias Ováricas/cirugía , Proyectos Piloto , Ganglio Linfático Centinela/patología , Agregado de Albúmina Marcado con Tecnecio Tc 99mAsunto(s)
Neoplasias Ováricas , Ganglio Linfático Centinela , Humanos , Femenino , Ganglio Linfático Centinela/cirugía , Ganglio Linfático Centinela/patología , Ganglios Linfáticos/cirugía , Ganglios Linfáticos/patología , Neoplasias Ováricas/patología , Biopsia del Ganglio Linfático Centinela , Escisión del Ganglio Linfático , Estadificación de NeoplasiasAsunto(s)
Ganglios Linfáticos/patología , Neoplasias Ováricas/patología , Biopsia del Ganglio Linfático Centinela/métodos , Ganglio Linfático Centinela/patología , Femenino , Humanos , Escisión del Ganglio Linfático/métodos , Ganglios Linfáticos/cirugía , Neoplasias Ováricas/cirugía , Ganglio Linfático Centinela/cirugíaRESUMEN
This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions. Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is the place for salvage PRRT-Lu? Whicht is the role of PRRT-Lu in the pediatric population? Which is the optimal sequencing of PRRT-Lu in advanced GEP NETs? Which is the place of PRRT-Lu in G3 NENs? These, and future developments such as inclusion new radiopharmaceuticals and combination therapy with different agents, such as radiosensitizers, will be discussed.
RESUMEN
BACKGROUND: Patient's breathing affects the quality of chest images acquired with positron emission tomography/computed tomography (PET/CT) studies. Movement correction is required to optimize PET quantification in clinical settings. We present a reproducible methodology to compare the impact of different movement compensation protocols on PET image quality. Static phantom images were set as reference values, and recovery coefficients (RCs) were calculated from motion compensated images for the phantoms in respiratory movement. Image quality was evaluated in terms of: (1) volume accuracy (VA) with the NEMA phantom; (2) concentration accuracy (CA) by six refillable inserts within the electron density CIRS phantom; and (3) spatial resolution (R) with the Jaszczak phantom. Three different respiratory patterns were applied to the phantoms. We developed an open-source package to automatically analyze VA, CA and R. We compared 10 different movement compensation protocols available in the Philips Gemini TF-64 PET/CT (4-, 6-, 8- and 10-time bins, 20%-, 30%-, 40%-window width in Inhale and Exhale). RESULTS: The homemade package provided RC values for VA, CA and R of 102 PET images in less than 5 min. Results of the comparison of the 10 different protocols demonstrated the feasibility of the proposed method for quantifying the variations observed qualitatively. Overall, prospective protocols showed better motion compensation than retrospective. The best performance was obtained for the protocol Exhale 30% (0.3 s after maximum Exhale position and window width of 30%) with RC[Formula: see text], RC[Formula: see text] and RC[Formula: see text]. Among retrospective protocols, 8 Phase protocol showed the best performance. CONCLUSION: We provided an open-source package able to automatically evaluate the impact of motion compensation methods on PET image quality. A setup based on commonly available experimental phantoms is recommended. Its application for the comparison of 10 time-based approaches showed that Exhale 30% protocol had the best performance. The proposed framework is not specific to the phantoms and protocols presented on this study.
RESUMEN
Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms which arise from neuroendocrine cells that are distributed widely throughout the body. Although heterogenous, many of them share their ability to overexpress somatostatin receptors (SSTR) on their cell surface. Due to this, SSTR and somatostatin have been a large subject of interest in the discovery of potential biomarkers and treatment options for the disease. The aim of this review is to describe the molecular characteristics of somatostatin and somatostatin receptors and its application in diagnosis and therapy on patients with NENs as well as the use in the near future of somatostatin antagonists.
RESUMEN
Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (177Lu-DOTA0 Tyr 3 octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish practical guidance for the management and prevention of the most common hormonal crises during radionuclide treatment with Lu-DOTA-TATE: carcinoid syndrome (CS) and catecholamine hypersecretion, as well as to provide a brief commentary on other infrequent metabolic complications. To establish a practical approach, a systematic review was performed. This systematic review was developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and conducted using MEDLINE (accessed from PubMed), Google Scholar and ClinicalTrials.gov. Literature searches found 449 citations, and finally nine were considered for this systematic review.
RESUMEN
BACKGROUND: Prostate cancer (PCa) represents one of the most common types of cancers facing the male population. Nowadays, to confirm PCa, systematic or multiparametric MRI-targeted transrectal or transperineal biopsies of the prostate are required. However, due to the lack of an accurate imaging technique capable to precisely locate cancerous cells in the prostate, ultrasound biopsies sample random parts of the prostate and, therefore, it is possible to miss regions where those cancerous cells are present. In spite of the improvement with multiparametric MRI, the low reproducibility of its reading undermines the specificity of the method. Recent development of prostate-specific radiotracers has grown the interest on using positron emission tomography (PET) scanners for this purpose, but technological improvements are still required (current scanners have resolutions in the range of 4-5 mm). RESULTS: The main goal of this work is to improve state-of-the-art PCa imaging and diagnosis. We have focused our efforts on the design of a novel prostate-dedicated PET scanner, named ProsPET. This system has small scanner dimensions defined by a ring of just 41 cm inner diameter. In this work, we report the design, implementation, and evaluation (both through simulations and real data) of the ProsPET scanner. We have been able to achieve < 2 mm resolution in reconstructed images and high sensitivity. In addition, we have included a comparison with the Philips Gemini-TF scanner, which is used for routine imaging of PCa patients. The ProsPET exhibits better contrast, especially for rod sizes as small as 4.5 mm in diameter. Finally, we also show the first reconstructed image of a PCa patient acquired with the ProsPET. CONCLUSIONS: We have designed and built a prostate specific PET system, with a small footprint and improved spatial resolution when compared to conventional whole-body PET scanners. The gamma ray impact within each detector block includes accurate DOI determination, correcting for the parallax error. The potential role of combined organ-dedicated prostate-specific membrane antigen (PSMA) PET and ultrasound devices, as a prebiopsy diagnostic tool, could be used to guide sampling of the most aggressive sites in the prostate.
RESUMEN
We present a case of an unexpected focally increased radiotracer uptake in an artificial eye in an FDG-PET/CT scan that was performed on a woman with a history of choroidal melanoma. It is crucial to know the type of prosthesis used and the timing of replacement for a correct interpretation of the findings. Recently, an FDG PET/CT was proposed to monitor the vascularity of the prosthesis instead of gadolinium MRI or of Tc bone scintigraphy.
Asunto(s)
Ojo Artificial/efectos adversos , Fluorodesoxiglucosa F18/farmacocinética , Tomografía Computarizada por Tomografía de Emisión de Positrones , Radiofármacos/farmacocinética , Femenino , HumanosRESUMEN
AIM: To analyze clinical profile and management of patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice according to age and to ascertain rates of thromboembolic and bleeding events during rivaroxaban therapy. METHODS: Retrospective study of nonvalvular atrial fibrillation patients that started rivaroxaban therapy between May 2013 and February 2017 in the cardiology department of two hospitals from Huesca, Spain. RESULTS: A total of 137 patients (mean age 78.2 ± 8.9 years; CHA2DS2-VASc 3.5 ± 1.3; HAS-BLED 1.6 ± 0.7) were included. Comorbidity was common. After a mean duration of treatment of 30.5 ± 17.2 months, no strokes were reported. Rates of transient ischemic attack, major bleeding and intracranial bleeding were low. CONCLUSION: In this cohort of elderly and highly comorbid patients treated with rivaroxaban, rates of thromboembolic and bleeding events were low.
Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Inhibidores del Factor Xa/uso terapéutico , Hemorragia/epidemiología , Rivaroxabán/uso terapéutico , Accidente Cerebrovascular/prevención & control , Tromboembolia/epidemiología , Factores de Edad , Anciano , Anciano de 80 o más Años , Fibrilación Atrial/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina , Estudios Retrospectivos , España , Accidente Cerebrovascular/etiologíaRESUMEN
Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B (SDHB) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of metronomic schemes (MS) of chemotherapy in mPHEO/PGL treatment. We report 2 patients with SDHB-related mPGL who received a regimen consisting of MS temozolomide (TMZ) and high-dose lanreotide after progression on both CVD chemotherapy and high-dose lanreotide. Molecular profiling of the tumor tissue from both patients revealed hypermethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter. In one patient, progression-free survival was 13 months and the second patient remained under treatment after 27 months of stabilization of metabolic response of his disease. Treatment was well tolerated, and adverse effects were virtually absent. A modification in the scheme of TMZ from standard schemes to MS is safe and feasible and can be considered in patients with progressive mPHEO/PGL refractory to dacarbazine in standard doses.
RESUMEN
BACKGROUND: The purpose of this study is to present our first results of sentinel node analysis (SLN) by one step nucleic acid amplification (OSNA) in routine clinical practice in our centre and compare them with the results of classic histopathological analysis in a historical cohort from our same institution. METHODS: 407 patients (total study population) with early breast cancer and no clinical nodal involvement underwent SLN biopsy in our institution. The SLN was analysed by OSNA in 164 biopsies. OSNA results were compared with the conventional histopathology study of 244 patients who had undergone SLN biopsy previously. The characteristics of the patients in both groups were evaluated and a comparison was made of the rate of metastases detected by both methods and of the surgical procedures needed in each group. We also investigated the state of non-sentinel lymph nodes if micrometastases where found in SLN. RESULTS: SLN biopsy result was considered as positive in 45 patients (28%) in the OSNA group and in 58 in the historical group (24%). There was no difference in the rate of macrometastases (16,5% for OSNA, 20% for HE) but we found differences in the rate of micrometastases (11% for OSNA and 3,6% for HE p = 0.0007). Axillary lymphadenectomy (ALND) was performed in 43/45 cases in the OSNA group and in 51/58 of the historical group. In all patients diagnosed by OSNA, ALND was performed during the initial surgical procedure. In the historical cohort ALND was performed during the initial surgical procedure in 41 patients and in a second surgical procedure in 10 patients. Patients from both groups with micrometastases in the SLN had no metastases in other nodes when the ALND was performed. CONCLUSIONS: OSNA analysis allows the detection of SLN metastases as precisely as conventional pathology with an increased detection of micrometastases. The OSNA method can reduce the need of a deferred lymphadenectomy.
Asunto(s)
Neoplasias Cerebelosas/diagnóstico por imagen , Meduloblastoma/diagnóstico por imagen , Recurrencia Local de Neoplasia/diagnóstico por imagen , Octreótido/análogos & derivados , Adulto , Neoplasias Cerebelosas/complicaciones , Neoplasias Cerebelosas/cirugía , Cerebelo/diagnóstico por imagen , Epilepsia/diagnóstico por imagen , Epilepsia/etiología , Humanos , Masculino , Meduloblastoma/complicaciones , Meduloblastoma/cirugía , Recurrencia Local de Neoplasia/complicaciones , Radiografía , Cintigrafía , RadiofármacosRESUMEN
Objetivo Evaluar las diferentes características diagnósticas de la función renal relativa (FRR) y de la función renal relativa normalizada por volumen renal relativo (FRRN), con el fin de analizar la posible mejora diagnóstica que implicaría su uso conjunto. Métodos Hemos estudiado con 99mTc-DMSA 952 unidades renales (riñones individuales), que pertenecían a 476 pacientes pediátricos (269 niñas) de edades comprendidas entre 0 y 11 años. De ellas, 355 unidades renales se consideraron patológicas a partir del análisis visual gammagráfico. Se determinaron los puntos de corte más apropiados para establecer los valores normales de las funciones FRR y FRRN, considerando como patrón de referencia al análisis visual gammagráfico. Se realizaron curvas ROC y se calculó el índice J de Youden y la exactitud para diferentes puntos de corte desde 42 por ciento hasta 50 por ciento, tanto para la FRR como para la FRRN. Se realizó también un análisis bayesiano (global y parcial clasificando las unidades renales por indicaciones clínicas) de la FRR y la FRRN. Resultados Para la FRR el mejor punto de corte fue 45 por ciento y para la FRRN fue 47 por ciento. El análisis bayesiano global mostró mejores resultados de los diferentes parámetros estadísticos para la FRRN. El análisis bayesiano parcial indicaba un importante incremento de la sensibilidad en pacientes con patología de dilatación de vía: de 10 por ciento (FRR) a 74.6 por ciento (FRRN); y con pielonefritis aguda: de 29.2 por ciento (FRR) a 66.2 por ciento (FRRN) mientras que en pacientes con nefropatías crónicas la sensibilidad fue similar (70.1 por ciento). Conclusión El cálculo de la FRRN (punto de corte 47 por ciento) proporciona información útil y complementaria a la FRR, ya que cuantifica la calidad relativa del riñón independientemente del volumen renal y refleja mejor los hallazgos gammagráficos.
Purpose To assess the different diagnostic features of relative renal function (RRF) and volume normalized relative renal function (NRRF) with the aim of analysing the possible diagnostic improvement that would imply their joint use. Methods We studied 952 kidneys with 99mTc-DMSA, belonging to 476 paediatric patients (269 girls) aged 0-11 years. 355 out of total were considered pathologic (visual analysis). The most appropriate cut-off points for establishing normality of RRF and NRRF were determined, considering as gold standard the visual scintigraphic analysis. R.O.C. curves were performed, J Youden index and accuracy were calculated for the different cut-off points from 42 percent to 50 percent for RRF and NRRF. A bayesian analysis (global and partial according to clinical indications) of RRF and NRRF was also performed. Results For RRF the better cut-off point was 45 percent and for NRRF 47 percent. The global bayesian analysis showed better values of the different statistical parameters for NRRF. Partial bayesian analysis indicated an important increment of sensitivity in patients with dilated pyelocalicial system: from 10 percent (RRF) to 74.6 percent (NRRF); and acute pyelonephritis: from 29.2 percent (RRF) to 66.2 percent (NRRF) while the sensitivity in patients with chronic nephropathy remained stable (70.1 percent). Conclusion NRRF calculation (cut-off 47 percent) provides useful and additional information to RRF, as it quantifies the relative quality of kidney tissue regardless of renal volume and better reflects better the scintigraphic findings.
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Preescolar , Niño , Pruebas de Función Renal/métodos , Radiofármacos , Riñón , Interpretación Estadística de Datos , Curva ROC , Estudios Retrospectivos , Radiofármacos/farmacocinética , Riñón/fisiopatología , Riñón/metabolismo , Sensibilidad y Especificidad , Valor Predictivo de las Pruebas , /farmacocinéticaRESUMEN
A prospective study of 81 heart transplant (HT) patients was carried out in order to evaluate the evolution of brain natriuretic peptide (BNP) levels in HT patients and compare them with the degree of rejection as determined by endomyocardial biopsy. All patients were subjected to endomyocardial biopsy (532), and determination of BNP and creatinine levels as well as hemodynamic parameters. A control group of 36 volunteers was included. BNP values were significantly greater in HT patients than in healthy volunteers. In the first 3 months, BNP levels in patients with treatable rejection were significantly greater than in patients without graft rejection, although evident overlapping was observed in both distributions and discriminatory potential was low. After the third month, BNP values were similar in patients with and without rejection. Creatinine levels were observed to increase over time after transplantation, but no correlation was observed between the creatinine and BNP levels. A significant positive correlation was observed between BNP and right ventricle and pulmonary arterial pressures.
Asunto(s)
Endocardio/metabolismo , Rechazo de Injerto/sangre , Trasplante de Corazón , Miocardio/metabolismo , Péptido Natriurético Encefálico/sangre , Adolescente , Adulto , Anciano , Biopsia , Creatinina/sangre , Femenino , Rechazo de Injerto/fisiopatología , Hemodinámica , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Curva ROC , Valores de Referencia , Factores de TiempoRESUMEN
Objetivo: El objetivo de este trabajo es calcular la fracción de eyección (FE) mediante ventriculografía isotópica en los pacientes tratados con antraciclinas, intentando analizar la dosis de adriamicina que condiciona la cardiotoxicidad. Material y método: Se realizó una revisión retrospectiva de las historias clínicas de 28 pacientes procedentes del Servicio de Oncología, a los que se les había practicado más de una ventriculografía isotópica, la segunda tras tratamiento con antraciclinas. Estudiamos 12 mujeres y 16 varones de edades comprendidas entre 16 y 72 años (media 43, mediana 45 años) con diferentes diagnósticos oncológicos siendo los más frecuentes: Sarcomas (39 por ciento); Carcinoma de mama (22 por ciento) y Linfoma no-Hodgkin (22 por ciento). Calculamos para cada paciente la dosis total de antraciclinas recibidas (adriamicina y 4-epirrubicina) incluyendo también las antraciclinas recibidas antes del primer estudio isotópico (cardiotoxicidad acumulada). Debido a que la 4-epirrubicina es menos cardiotóxica que la adriamicina se convierten las cifras de 4-epirubicina a adriamicina (siguiendo la relación: 50mg/m2 de adriamicina se corresponden con 75mg/m2 de 4-epirrubicina). Se compararon las medias previas y tras tratamiento de las FE de ambos ventrículos y se calculó si existían diferencias mediante el test de la t de Student para datos apareados. Resultados: La t de Student de las medias de las FE del Ventrículo izquierdo (V.I.) antes y tras el tratamiento fue 4.08 (existen diferencias estadísticamente significativas para una p<0.01) sin embargo para el ventrículo derecho la t fue 1.79 lo que indica que no existieron diferencias estadísticamente significativas (p=0.09)...
Asunto(s)
Humanos , Masculino , Adolescente , Adulto , Femenino , Persona de Mediana Edad , Antraciclinas , Ventriculografía con Radionúclidos/métodos , Antraciclinas , Neoplasias , Volumen SistólicoRESUMEN
Previous reviews have include prostate, breast, bladder and colon cancer and lymphoma among the causes of a super bone scan but have not included stomach cancer. We report a 58 year-old female with an infiltrative gastric adenocarcinoma extended to the minor curvature and posterior side of fundus. Bone scintigraphy showed diffuse increased uptake typical of a "superscan" indicating bone metastases diffusely invading the bone marrow. Gastric carcinoma should be considered in the differential diagnosis of a "superscan" pattern